ArriVent: firmonertinib shows 81.8% ORR in EGFR PACC mutant NSCLC Phase 1b data

ArriVent BioPharma, Inc.

81.8% ORR and 63.6% confirmed ORR by BICR at 240mg dose in first-line EGFR PACC mutant NSCLC.
46.2% confirmed CNS ORR (6/13) in patients with brain metastases at baseline.
Median duration of response not reached; 90.9% (20/22) of confirmed responders remain on study.
No Grade 4/5 TRAEs or treatment discontinuations due to TRAEs; safety consistent with prior data.
Data presented at WCLC 2024; ArriVent plans virtual webinar on September 9, 2024 at 4:30pm ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.